Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders
17 Avril 2019 - 2:55PM
Amsterdam, The Netherlands, April 17, 2019 -
Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that it has convened an
extraordinary general meeting of shareholders ("EGM") to obtain shareholder approval pursuant to
section 2:107a of the Dutch Civil Code for the proposed acquisition
of CytoSen Therapeutics, Inc. that was announced earlier today. The
EGM is to be held on Wednesday, May 29, 2019 at 10:00am CEST at the
Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW
Amsterdam, The Netherlands.
A shareholders circular including
and encompassing the notice and agenda (including explanatory
notes) for the EGM as well as the proxy form are available on the
Investors' section of the Kiadis Pharma website at:
http://www.kiadis.com/investors/shareholders-meetings/.
For more information, please
contact:
Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
a.sullivan@kiadis.com
Maryann Cimino, Manager, Corporate Affairs
Tel. +1 617 710 7305
m.cimino@kiadis.com
|
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com |
About Kiadis
Pharma
Kiadis Pharma is developing its lead product candidate, ATIR101,
for use in conjunction with haploidentical HSCT for adult blood
cancers to address key limitations of haploidentical HSCT, without
prophylactic immunosuppression and its associated morbidity and
mortality. Based on the positive results from the single dose Phase
II CR-AIR-007 study, the Company submitted a marketing
authorization application to the European Medicines Agency in April
2017 for approval of ATIR101 as an adjunctive treatment in
haploidentical HSCT for high risk adult hematological malignancies.
If the product is conditionally approved, Kiadis Pharma intends to
launch ATIR101 in Europe through its own commercial organization by
year end 2019.
In December 2017, Kiadis Pharma
commenced an international, multicenter, randomized and controlled
Phase III clinical trial of ATIR101 against the Post-Transplant
Cyclophosphamide, or PTCy protocol, the main protocol used to
perform a haploidentical HSCT. The trial will be performed in 250
patients with acute leukemia and myelodysplastic syndrome at
approximately 50 sites in the United States, Canada, Europe and
certain additional countries. ATIR101 received regenerative
medicine advanced therapy designation from the FDA in September
2017, which provides benefits that are materially equivalent to a
breakthrough designation from the FDA. In addition, ATIR101 has
been granted multiple orphan Drug designations both in the European
Union and the United States.
The Company's shares are listed on
Euronext Amsterdam and Brussels under the ticker KDS.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology or our
ability to develop and successfully integrate new assets and
product programs into our business, can all cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither Kiadis Pharma nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire